Clinic
NYU Langone Hospitals
NYU Langone Hospitals was paid $303.18M by Medicaid between Jan 2018 and Dec 2024, across 535 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 15% of everything it billed.
33Billing provider infoNYU LANGONE HOSPITALS
BROOKLYN, NY 11220
BROOKLYN, NY 11220
33aNPI1619341716assigned 11/30/2015
33bProvider typeFederally Qualified Health Center (FQHC)
28Total paid$303.18M
24GClaims4,406,436
24DCodes billed535
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Federally Qualified Health Center (FQHC) providers in New York
Rank by total paid#1 of 158
Median peer was paid$1.73M
This provider vs. median175×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 134,777 | $7.12M | |
| 2019 | 527,308 | $33.68M | |
| 2020 | 767,125 | $47.77M | |
| 2021 | 844,053 | $53.31M | |
| 2022 | 642,483 | $44.21M | |
| 2023 | 735,055 | $57.54M | |
| 2024incomplete | 755,635 | $59.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 15% | 488,964 | 412,175 | $45.85M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 12% | 253,130 | 125,580 | $37.59M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.7% | 255,935 | 204,037 | $29.29M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.3% | 88,118 | 73,463 | $9.97M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.2% | 66,604 | 55,192 | $9.74M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.2% | 45,355 | 42,999 | $9.69M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.7% | 52,064 | 28,573 | $8.06M |
| D0999 | Unspecified diagnostic procedure, by report | 2.4% | 184,354 | 55,774 | $7.43M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.4% | 35,710 | 33,920 | $7.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 33,098 | 31,490 | $6.50M |
| D0120 | Dental checkup, returning patientPeriodic oral evaluation - established patient | 1.9% | 156,855 | 63,540 | $5.80M |
| G0378 | Hospital observation service, per hour | 1.9% | 6,291 | 5,820 | $5.68M |
523 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 23,214 | $5.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 59,664 | $4.61M |
| 90686 | 1.4% | 138,199 | $4.39M | |
| D1120 | Dental cleaning, child | 1.4% | 74,804 | $4.29M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 47,599 | $4.20M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.1% | 41,825 | $3.48M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 20,882 | $3.27M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.0% | 33,805 | $3.08M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 37,500 | $3.03M |
| 36415 | Collection of venous blood by venipuncture | <1% | 81,342 | $2.74M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 99,557 | $2.62M |
| D1110 | Prophylaxis - adult | <1% | 38,285 | $2.56M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 25,062 | $2.38M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 22,427 | $2.38M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 24,369 | $2.27M |
| D1351 | Sealant - per tooth | <1% | 36,477 | $2.21M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12,552 | $1.94M |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 21,396 | $1.73M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,476 | $1.60M |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 33,268 | $1.58M |
| 90651 | <1% | 25,503 | $1.56M | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 21,474 | $1.52M |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 19,984 | $1.48M |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 4,354 | $1.42M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 25,978 | $1.35M |
| 93458 | <1% | 761 | $1.29M | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,717 | $1.24M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,534 | $1.13M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17,198 | $1.11M |
| Q3014 | Telehealth originating site facility fee | <1% | 8,499 | $1.10M |
| D0220 | Intraoral - periapical first radiographic image | <1% | 76,894 | $1.09M |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 899 | $1.07M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,634 | $1.07M |
| D0272 | Bitewings - two radiographic images | <1% | 33,902 | $1.07M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 18,655 | $1.05M |
| 93975 | <1% | 2,893 | $1.01M | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 23,012 | $1.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 6,020 | $992K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 7,585 | $946K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,319 | $923K |
| 90670 | <1% | 48,770 | $842K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 13,282 | $798K |
| 90656 | <1% | 21,847 | $781K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 52,159 | $736K |
| D0274 | Bitewings - four radiographic images | <1% | 32,269 | $719K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 4,184 | $695K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,052 | $684K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,836 | $662K |
| 90633 | <1% | 27,995 | $640K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 6,080 | $636K |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 422 | $633K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,395 | $591K |
| D0140 | Limited oral evaluation - problem focused | <1% | 18,927 | $588K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 5,656 | $586K |
| D1206 | Topical application of fluoride varnish | <1% | 23,735 | $571K |
| 81025 | <1% | 10,645 | $541K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,133 | $540K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 5,291 | $529K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 488 | $528K |
| 10E0XZZ | <1% | 728 | $507K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 20,874 | $494K |
| 95708 | <1% | 1,548 | $486K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 54,967 | $484K |
| 80076 | <1% | 35,645 | $480K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 4,457 | $422K |
| 90750 | <1% | 3,422 | $397K | |
| 99381 | <1% | 4,457 | $386K | |
| 86703 | <1% | 8,812 | $381K | |
| 90837 | Psychotherapy session, about an hour | <1% | 1,983 | $369K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,746 | $369K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 701 | $359K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 40,855 | $356K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,736 | $350K |
| C1769 | Guide wire | <1% | 1,979 | $338K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,657 | $337K |
| 93976 | <1% | 1,106 | $331K | |
| 76770 | <1% | 1,394 | $318K | |
| 90715 | <1% | 12,792 | $306K | |
| 86850 | <1% | 15,768 | $306K | |
| D9310 | <1% | 4,908 | $288K | |
| 97161 | <1% | 3,912 | $281K | |
| 90461 | <1% | 18,749 | $279K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,481 | $274K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,787 | $271K |
| 99385 | <1% | 2,567 | $261K | |
| 12001 | <1% | 951 | $260K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,867 | $255K |
| 76830 | Ultrasound, transvaginal | <1% | 4,514 | $255K |
| 84703 | <1% | 32,521 | $251K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,403 | $249K |
| 90746 | <1% | 4,358 | $244K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,289 | $242K |
| 59025 | Fetal non-stress test | <1% | 3,628 | $237K |
| 54161 | <1% | 193 | $232K | |
| 90681 | <1% | 14,285 | $228K | |
| 86900 | <1% | 15,839 | $224K | |
| 12011 | <1% | 780 | $220K | |
| 76641 | <1% | 2,429 | $217K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,110 | $205K |
| 85610 | <1% | 17,763 | $199K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,570 | $197K |
| 0002A | <1% | 5,079 | $196K | |
| 86901 | <1% | 15,833 | $195K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 2,640 | $194K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,708 | $193K |
| C7901 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 3,397 | $190K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13,256 | $189K |
| J3490 | Unclassified drugs | <1% | 27,317 | $189K |
| 82948 | <1% | 31,151 | $187K | |
| 0001A | <1% | 5,337 | $184K | |
| 97802 | <1% | 4,545 | $183K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 5,803 | $181K |
| 95700 | <1% | 958 | $180K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,424 | $173K |
| 90674 | <1% | 4,860 | $172K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 949 | $168K |
| 87631 | <1% | 3,298 | $167K | |
| 99386 | <1% | 1,480 | $162K | |
| 99401 | <1% | 2,633 | $158K | |
| D0160 | <1% | 4,936 | $155K | |
| 90620 | <1% | 5,355 | $154K | |
| 97162 | <1% | 2,235 | $150K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 73 | $150K |
| 90707 | <1% | 6,108 | $150K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 20,836 | $144K |
| 47562 | <1% | 68 | $143K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,366 | $143K |
| 77066 | Tomosynthesis, mammo | <1% | 1,044 | $136K |
| 76642 | <1% | 1,827 | $135K | |
| D0270 | <1% | 6,957 | $134K | |
| 58558 | <1% | 103 | $130K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 8,603 | $125K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,535 | $125K |
| 92550 | <1% | 3,211 | $120K | |
| 82803 | <1% | 10,362 | $119K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,995 | $116K |
| 99201 | <1% | 1,576 | $111K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,807 | $107K |
| 93970 | <1% | 433 | $107K | |
| 3E0234Z | <1% | 344 | $107K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,359 | $101K |
| 88342 | <1% | 2,182 | $96K | |
| 97803 | <1% | 3,516 | $96K | |
| D9430 | <1% | 1,981 | $94K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,983 | $94K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 561 | $93K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,428 | $91K |
| 92523 | <1% | 445 | $91K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,871 | $91K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 24 | $88K |
| 90685 | <1% | 2,599 | $84K | |
| 90734 | <1% | 3,193 | $82K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 846 | $82K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 110 | $78K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,648 | $77K |
| 88307 | <1% | 1,179 | $76K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 70 | $76K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,310 | $74K |
| D9110 | <1% | 2,068 | $71K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 68 | $71K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,582 | $70K |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 2,855 | $70K |
| 12002 | <1% | 255 | $69K | |
| 90732 | <1% | 899 | $68K | |
| 90716 | <1% | 3,452 | $68K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15,963 | $68K |
| 90677 | <1% | 892 | $67K | |
| 86580 | <1% | 3,235 | $67K | |
| 95816 | <1% | 222 | $67K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,169 | $66K |
| 76000 | <1% | 1,306 | $65K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 552 | $63K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 19,508 | $63K |
| 99397 | <1% | 821 | $63K | |
| 83880 | <1% | 4,239 | $60K | |
| 92526 | <1% | 837 | $60K | |
| D1354 | <1% | 2,591 | $59K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 424 | $58K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,349 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,236 | $55K |
| 88720 | <1% | 4,130 | $55K | |
| 99406 | <1% | 5,722 | $55K | |
| D0330 | Panoramic radiographic image | <1% | 2,178 | $54K |
| 90662 | <1% | 1,794 | $54K | |
| 93798 | <1% | 1,408 | $54K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,576 | $53K |
| 0004A | <1% | 1,353 | $52K | |
| 92250 | <1% | 1,214 | $52K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,384 | $49K |
| 76536 | <1% | 502 | $48K | |
| 99383 | <1% | 472 | $47K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 282 | $45K |
| 92579 | <1% | 1,332 | $45K | |
| 73630 | <1% | 2,945 | $44K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 642 | $43K |
| 99384 | <1% | 410 | $43K | |
| 92557 | <1% | 1,626 | $41K | |
| 88341 | <1% | 836 | $41K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,544 | $40K |
| 99173 | <1% | 806 | $39K | |
| 10060 | <1% | 163 | $39K | |
| 90648 | <1% | 2,669 | $38K | |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 14 | $37K |
| 0071A | <1% | 940 | $36K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 427 | $35K |
| 70486 | <1% | 1,122 | $34K | |
| 88304 | <1% | 1,140 | $33K | |
| 93971 | <1% | 713 | $33K | |
| 0072A | <1% | 826 | $33K | |
| 58300 | <1% | 402 | $33K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 429 | $32K |
| 97542 | <1% | 216 | $31K | |
| 70496 | <1% | 185 | $31K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 1,402 | $29K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,573 | $29K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,462 | $27K |
| 93325 | <1% | 1,375 | $26K | |
| 87428 | <1% | 566 | $26K | |
| 97165 | <1% | 368 | $24K | |
| 44970 | <1% | 12 | $24K | |
| J2704 | Injection, propofol, 10 mg | <1% | 19,017 | $24K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,159 | $24K |
| 90480 | <1% | 587 | $23K | |
| 99442 | <1% | 483 | $23K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,688 | $22K |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 24 | $22K |
| 93454 | <1% | 12 | $22K | |
| 93304 | <1% | 176 | $21K | |
| S9465 | Diabetic management program, dietitian visit | <1% | 195 | $21K |
| 90696 | <1% | 2,176 | $19K | |
| D1353 | <1% | 503 | $19K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,279 | $19K |
| 93320 | <1% | 307 | $19K | |
| 0012A | <1% | 456 | $18K | |
| S9140 | Diabetic management program, follow-up visit to non-md provider | <1% | 146 | $17K |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | <1% | 175 | $17K |
| 77061 | <1% | 713 | $17K | |
| D3330 | Endodontic therapy, molar tooth (excluding final restoration) | <1% | 65 | $17K |
| 90744 | <1% | 4,226 | $16K | |
| 99382 | <1% | 164 | $16K | |
| 90882 | <1% | 74 | $16K | |
| 77062 | <1% | 695 | $16K | |
| 73562 | <1% | 1,773 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,889 | $15K |
| 81002 | <1% | 2,471 | $15K | |
| 90473 | <1% | 2,548 | $15K | |
| D0190 | <1% | 752 | $15K | |
| 90749 | <1% | 849 | $14K | |
| 90697 | <1% | 3,587 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,397 | $14K |
| 0124A | <1% | 373 | $14K | |
| 72100 | <1% | 856 | $14K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 451 | $13K |
| 73610 | <1% | 2,060 | $12K | |
| D9219 | <1% | 270 | $12K | |
| 91320 | <1% | 115 | $12K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 119 | $12K |
| 0011A | <1% | 536 | $12K | |
| 80061 | Lipid panel | <1% | 1,150 | $12K |
| D4341 | <1% | 174 | $12K | |
| 58301 | <1% | 132 | $11K | |
| 72131 | <1% | 411 | $11K | |
| 96161 | <1% | 424 | $11K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 33 | $11K |
| D9991 | <1% | 367 | $11K | |
| 36416 | <1% | 1,805 | $10K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,099 | $10K |
| 73502 | <1% | 730 | $10K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 50 | $10K |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | <1% | 161 | $10K |
| 87070 | <1% | 3,220 | $10K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 2,135 | $10K |
| 94060 | <1% | 160 | $10K | |
| 0054A | <1% | 275 | $9K | |
| 36430 | <1% | 33 | $9K | |
| 29125 | <1% | 44 | $9K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 15 | $9K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 958 | $9K |
| 80053 | Comprehensive metabolic panel | <1% | 1,086 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,516 | $8K |
| 73030 | <1% | 1,865 | $8K | |
| 57454 | <1% | 28 | $8K | |
| 97166 | <1% | 132 | $8K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,820 | $8K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 81 | $8K |
| 88142 | <1% | 189 | $8K | |
| 76818 | <1% | 128 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,641 | $7K |
| C1753 | Catheter, intravascular ultrasound | <1% | 13 | $7K |
| 93321 | <1% | 386 | $7K | |
| 71250 | <1% | 87 | $7K | |
| D2331 | <1% | 91 | $7K | |
| 94729 | <1% | 158 | $7K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 9,406 | $6K |
| 81001 | <1% | 20,848 | $6K | |
| 81003 | <1% | 2,599 | $6K | |
| 90647 | <1% | 484 | $6K | |
| 99441 | <1% | 234 | $6K | |
| 77080 | <1% | 181 | $6K | |
| 97035 | <1% | 166 | $6K | |
| 73130 | <1% | 1,916 | $6K | |
| 90688 | <1% | 154 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,388 | $6K |
| 85730 | <1% | 10,998 | $6K | |
| 87254 | <1% | 164 | $6K | |
| 0003A | <1% | 161 | $6K | |
| 90649 | <1% | 120 | $6K | |
| D0603 | <1% | 3,784 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,111 | $5K |
| 90632 | <1% | 162 | $5K | |
| 0064A | <1% | 137 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,061 | $5K |
| 86780 | <1% | 1,088 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,571 | $5K |
| 73110 | <1% | 1,351 | $5K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 135 | $5K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 774 | $4K |
| 97116 | <1% | 136 | $4K | |
| 94727 | <1% | 143 | $4K | |
| 84484 | <1% | 15,480 | $4K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 1,687 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,443 | $4K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 836 | $4K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,921 | $4K |
| 73560 | <1% | 328 | $4K | |
| 99443 | <1% | 52 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,022 | $4K |
| 92978 | <1% | 14 | $4K | |
| 76870 | <1% | 171 | $4K | |
| 88184 | <1% | 71 | $4K | |
| 83735 | <1% | 9,863 | $4K | |
| 90380 | <1% | 178 | $4K | |
| 73590 | <1% | 1,242 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 952 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,966 | $3K |
| 85027 | <1% | 1,796 | $3K | |
| 74220 | <1% | 32 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 637 | $3K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,222 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $3K |
| 86360 | <1% | 81 | $3K | |
| 83690 | <1% | 15,450 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,853 | $3K |
| 84702 | <1% | 5,675 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,719 | $3K |
| 70498 | <1% | 135 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 199 | $3K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,284 | $3K |
| 72195 | <1% | 13 | $3K | |
| 73564 | <1% | 325 | $3K | |
| 90474 | <1% | 265 | $3K | |
| 87507 | <1% | 38 | $3K | |
| 82962 | <1% | 1,014 | $3K | |
| 95705 | <1% | 14 | $2K | |
| D0321 | <1% | 116 | $2K | |
| 90381 | <1% | 129 | $2K | |
| T2101 | Human breast milk processing, storage and distribution only | <1% | 68 | $2K |
| 72128 | <1% | 190 | $2K | |
| 99496 | <1% | 15 | $2K | |
| D9995 | <1% | 66 | $2K | |
| 11981 | <1% | 24 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,551 | $2K |
| 90839 | <1% | 15 | $2K | |
| 96376 | <1% | 1,834 | $2K | |
| 90661 | <1% | 42 | $2K | |
| 97760 | <1% | 45 | $2K | |
| 72170 | <1% | 1,091 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 66 | $2K |
| 92083 | <1% | 23 | $2K | |
| 0081A | <1% | 52 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 417 | $2K |
| 74018 | <1% | 465 | $2K | |
| 97163 | <1% | 25 | $2K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 184 | $2K |
| 88185 | <1% | 71 | $2K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 4,341 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 168 | $2K |
| 87040 | <1% | 5,072 | $2K | |
| 86803 | <1% | 362 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 59 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 548 | $2K |
| 73080 | <1% | 853 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,353 | $1K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 217 | $1K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 708 | $1K |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 66 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 423 | $1K |
| 82570 | <1% | 655 | $1K | |
| G0010 | Administration of hepatitis b vaccine | <1% | 106 | $1K |
| 73060 | <1% | 467 | $1K | |
| 84439 | <1% | 1,192 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,488 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,289 | $1K |
| 86140 | <1% | 2,736 | $1K | |
| 93017 | <1% | 20 | $1K | |
| 0134A | <1% | 31 | $1K | |
| 0082A | <1% | 28 | $1K | |
| 82607 | <1% | 400 | $1K | |
| 91300 | <1% | 9,933 | $1K | |
| D9248 | <1% | 54 | $1K | |
| 85384 | <1% | 424 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 865 | $1K |
| 84100 | <1% | 4,091 | $998.90 | |
| 73090 | <1% | 836 | $992.14 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 196 | $934.81 |
| 90698 | <1% | 4,708 | $933.09 | |
| D1999 | <1% | 18 | $900.00 | |
| 87186 | <1% | 1,283 | $855.88 | |
| 90710 | <1% | 1,345 | $825.21 | |
| 0013A | <1% | 20 | $823.45 | |
| D4342 | <1% | 27 | $766.55 | |
| D2390 | <1% | 24 | $764.50 | |
| 99152 | <1% | 415 | $690.57 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 896 | $675.44 |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 16 | $639.82 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 442 | $638.12 |
| 87430 | <1% | 136 | $615.11 | |
| 0052A | <1% | 15 | $596.63 | |
| 96380 | <1% | 24 | $594.48 | |
| 76882 | <1% | 15 | $590.41 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 48 | $586.88 |
| 84156 | <1% | 299 | $578.70 | |
| 0154A | <1% | 14 | $571.47 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 177 | $567.46 |
| 86357 | <1% | 17 | $514.09 | |
| 96367 | <1% | 16 | $506.03 | |
| 85652 | <1% | 1,897 | $503.94 | |
| 73010 | <1% | 130 | $499.82 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 580 | $480.94 |
| 84112 | <1% | 12 | $475.65 | |
| 73552 | <1% | 144 | $465.48 | |
| 85379 | <1% | 2,577 | $449.47 | |
| 83605 | <1% | 1,537 | $434.36 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 920 | $432.97 |
| 73140 | <1% | 297 | $425.32 | |
| 82728 | <1% | 354 | $397.67 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 140 | $393.73 |
| 86923 | <1% | 15 | $380.41 | |
| 86359 | <1% | 17 | $354.09 | |
| 88172 | <1% | 12 | $350.37 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 2,082 | $345.90 |
| 87340 | <1% | 115 | $324.99 | |
| 82248 | <1% | 135 | $315.78 | |
| 88173 | <1% | 13 | $304.88 | |
| 84550 | <1% | 180 | $299.31 | |
| D2330 | <1% | 13 | $257.35 | |
| 87205 | <1% | 523 | $254.20 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 121 | $244.66 |
| 82550 | <1% | 1,304 | $241.77 | |
| 74019 | <1% | 97 | $238.89 | |
| D0240 | <1% | 14 | $221.21 | |
| 91307 | <1% | 310 | $215.75 | |
| D1330 | <1% | 1,794 | $210.23 | |
| 86706 | <1% | 131 | $195.18 | |
| 99407 | <1% | 25 | $184.17 | |
| 80320 | <1% | 1,325 | $182.15 | |
| 82746 | <1% | 108 | $175.50 | |
| 87275 | <1% | 67 | $171.54 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 723 | $166.80 |
| 92133 | <1% | 13 | $153.02 | |
| 86769 | <1% | 13 | $151.68 | |
| 73120 | <1% | 25 | $143.72 | |
| 90723 | <1% | 328 | $143.58 | |
| 91312 | <1% | 309 | $142.93 | |
| 73100 | <1% | 55 | $132.62 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 244 | $112.53 |
| 86704 | <1% | 126 | $110.66 | |
| 83540 | <1% | 76 | $103.63 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 14 | $101.09 |
| 82247 | <1% | 84 | $99.43 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 28 | $98.24 |
| 72070 | <1% | 26 | $96.67 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,934 | $93.92 |
| 91305 | <1% | 201 | $88.07 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 46 | $87.95 |
| D9920 | <1% | 13 | $71.86 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 38 | $61.93 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 33 | $54.92 |
| 83550 | <1% | 48 | $54.31 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 95 | $53.25 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 68 | $50.93 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 26 | $49.90 |
| 91308 | <1% | 110 | $49.86 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 27 | $49.56 |
| 73620 | <1% | 13 | $42.82 | |
| 83615 | <1% | 27 | $42.16 | |
| 82010 | <1% | 265 | $34.98 | |
| 90713 | <1% | 48 | $33.53 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 39 | $29.00 |
| 90700 | <1% | 383 | $28.71 | |
| 87899 | <1% | 14 | $24.91 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 73 | $21.37 |
| 85347 | <1% | 26 | $20.11 | |
| 82150 | <1% | 15 | $16.54 | |
| 91315 | <1% | 13 | $10.30 | |
| 91313 | <1% | 18 | $9.95 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 210 | $9.87 |
| 86592 | <1% | 12 | $9.53 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 954 | $8.44 |
| 91301 | <1% | 696 | $5.94 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 58 | $2.25 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 23 | $1.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 71 | $0.21 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 141 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 64 | $0.00 |
| 81007 | 0% | 134 | $0.00 | |
| 84145 | 0% | 126 | $0.00 | |
| 99080 | 0% | 55 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 13 | $0.00 |
| 71100 | 0% | 27 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 16 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 122 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 72 | $0.00 |
| 87075 | 0% | 12 | $0.00 | |
| D1310 | 0% | 1,770 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 197 | $0.00 |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 16 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| 80329 | 0% | 121 | $0.00 | |
| 86361 | 0% | 56 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 12 | $0.00 |
| 81015 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, WESLEY (VP REVENUE CYCLE)
Parent organizationNYU LANGONE HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| NYU Langone Hospitals | New York, NY | $238.69M |
| NYU Langone Hospitals | New York, NY | $117.59M |
| NYU Langone Hospitals | Mineola, NY | $69.77M |
| NYU Langone Hospitals | New York, NY | $32.22M |
| NYU Langone Hospitals | New York, NY | $3.50M |
| NYU Langone Hospitals | Brooklyn, NY | $453K |
| NYU Langone Hospitals | Brooklyn, NY | $99K |
| NYU Langone Hospitals | Brooklyn, NY | $9K |
| NYU Hospitals Center | New York, NY | $55.44 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.